Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Propylthiouracil
Drug ID BADD_D01869
Description A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)
Indications and Usage Used to manage hyperthyroidism which is due to an overactive thyroid gland (Grave's disease).
Marketing Status approved; investigational
ATC Code H03BA02
DrugBank ID DB00550
KEGG ID D00562
MeSH ID D011441
PubChem ID 657298
TTD Drug ID D00MIN
NDC Product Code 33342-314; 67253-651; 68084-964; 49452-6112; 20012-0001; 0228-2348; 70752-171; 59348-0013; 65319-1059
UNII 721M9407IY
Synonyms Propylthiouracil | 6-Propyl-2-Thiouracil | 6 Propyl 2 Thiouracil
Chemical Information
Molecular Formula C7H10N2OS
CAS Registry Number 51-52-5
SMILES CCCC1=CC(=O)NC(=S)N1
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.0010.009404%Not Available
Glomerulonephritis20.05.01.001; 10.02.01.0060.009404%Not Available
Glomerulonephritis rapidly progressive20.05.01.004; 10.04.04.0080.023510%Not Available
Granulocytopenia01.02.03.003--Not Available
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.0060.014106%
Haemoglobin13.01.05.018--Not Available
Haemoptysis02.11.04.009; 24.07.01.006; 22.02.03.0040.023510%Not Available
Headache17.14.01.001--
Hepatic encephalopathy17.13.01.003; 09.01.03.0060.009404%Not Available
Hepatic failure09.01.03.0020.023510%
Hepatitis09.01.07.004--Not Available
Hepatotoxicity09.01.07.009; 12.03.01.008--Not Available
Hyperemesis gravidarum18.02.02.010; 07.01.07.0090.009404%Not Available
Hypersensitivity10.01.03.0030.014106%
Hypersensitivity vasculitis23.06.02.005; 10.02.02.017; 01.01.04.008; 24.12.04.0130.009404%Not Available
Hyperthyroidism14.11.01.011; 05.02.02.0010.023510%
Hypoprothrombinaemia01.01.01.001--Not Available
Hypothyroidism14.11.01.012; 05.02.03.0010.014106%
Hypoxia22.02.02.0030.009404%
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Jaundice01.06.04.004; 23.03.03.030; 09.01.01.0040.023510%Not Available
Jaundice cholestatic09.01.01.005--Not Available
Leukopenia01.02.02.001--Not Available
Lung infiltration22.01.02.004--Not Available
Lymphadenopathy01.09.01.002--Not Available
Myalgia15.05.02.001--
Nausea07.01.07.001--
Nephritis20.05.02.001--Not Available
Neuritis17.09.03.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene